Patrick Soon-Shiong, MD, a physician, surgeon and scientist, invented and developed the revolutionary drug Abraxane, which has received FDA approval for the treatment of metastatic breast cancer, lung cancer and advanced pancreatic cancer.
Abraxane is the only drug of its kind to be approved in first line therapies across this broad spectrum of tumors in both the U.S. and EU. Over the course of his career he has pioneered novel therapies for both diabetes and cancer, published over 100 scientific papers, and has over 170 issued patents worldwide on groundbreaking advancements spanning myriad fields of technology and medicine. As a surgeon, Dr. Soon-Shiong performed the world’s first encapsulated human islet transplant, the first engineered islet cell transplant and the first pig to man islet cell transplant in diabetic patients
From 1997- 2010, Dr. Soon-Shiong served as founder, Chairman and CEO of two global pharmaceutical companies American Pharmaceutical Partners and Abraxis BioScience. In 2008, Dr. Soon-Shiong sold American Pharmaceutical Partners (NASDAQ: APP) to Fresenius for approximately $5.9 billion and in 2010, sold Abraxis Bio Science to Celgene for approximately $3.8 billion.
In January 2016, Dr. Soon-Shiong announced the formation of Cancer Moonshot 2020, a comprehensive collaboration of researchers, insurers and pharmaceutical companies that seeks to accelerate the potential of combined immunotherapy in the treatment of cancer. The initiative has a goal of initiating Phase 2 trials in 20,000 cancer patients within the next three years and the launch of a revolutionary molecular diagnostic, GPS Cancer enabling analysis of the whole gnome and target proteomics, transcending genomics to the era of clinic proteomics in cancer.
Dr. Soon-Shiong currently serves as Chairman and CEO of NantKwest (NK), a Nasdaq listed immunotherapy company focusing on Natural Killer cells and Chairman and of NantHealth (NH), a Nasdaq listed transformational healthcare company converging biomolecular medicine and bioinformatics with technology services to empower physicians, patients, payers, pharma and researchers to transcend the traditional barriers of today’s healthcare system.
Dr. Soon-Shiong is Chairman of the Chan Soon-Shiong Family Foundation and Chairman and CEO of the Chan Soon-Shiong Institute of Molecular Medicine, a non-profit medical research organization. He co-chairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America. He is an Adjunct Professor of Surgery at UCLA, and a visiting Professor at the Imperial College of London and Dartmouth College. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award.
In April 2016, Dr. Soon-Shiong received the Franklin Institute Award for his visionary leadership and commitment to advancing medical and scientific research and bringing new treatment options to cancer patients. Also in April 2016, Dr. Soon-Shiong was honored at the Vatican and received the 2016 Pontifical Key Visionary Award. The award recognized Dr. Soon-Shiong’s contribution to medical innovation and visionary leaders who change the course of history and reduce suffering on a global scale by blending visionary thinking with real action.
Dr. Soon-Shiong, who was born and raised in apartheid South Africa, lives in Los Angles and is a citizen of the United States.